lonafarnib has been researched along with Calcinosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abutaleb, NO; Atchison, L; Bedapudi, A; Cao, K; Choi, L; Gete, Y; Shores, K; Truskey, GA | 1 |
| Baltrusaitis, K; Braddock, DT; Cleveland, RH; D'Agostino, RB; Gordon, CM; Gordon, LB; Kieran, MW; Kleinman, ME; Li, X; Liang, MG; Massaro, J; Snyder, B; Walters, M | 1 |
2 other study(ies) available for lonafarnib and Calcinosis
| Article | Year |
|---|---|
Lonafarnib and everolimus reduce pathology in iPSC-derived tissue engineered blood vessel model of Hutchinson-Gilford Progeria Syndrome.
Topics: Atherosclerosis; Calcinosis; Endothelial Cells; Everolimus; Humans; Induced Pluripotent Stem Cells; Lamin Type A; Progeria | 2023 |
Extraskeletal Calcifications in Hutchinson-Gilford Progeria Syndrome.
Topics: Calcinosis; Calcium; Child; Child, Preschool; Creatinine; Female; Fibroblast Growth Factor-23; Humans; In Vitro Techniques; Lamin Type A; Male; Parathyroid Hormone; Piperidines; Pravastatin; Progeria; Pyridines; Zoledronic Acid | 2019 |